NCT00299234View on ClinicalTrials.gov

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL

PHASE4TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Atomoxetine

titration schedule: 0.5 to 1.5 mg/kg/day

Trial Locations (1)

23510

Monarch Medical Research - Child and Adolescent Neurology, Norfolk

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Monarch Medical Research

OTHER

NCT00299234 - Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL | Biotech Hunter | Biotech Hunter